Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$15.51 +1.2%	$14.74	$9.57 ▼ $30.41	$2.12B	0.96	1.54 million shs	1.54 million shs
BHC Bausch Health Cos	$6.11 -1.1%	$5.02	$3.96 ▼ $9.85	$2.29B	0.28	2.62 million shs	2.30 million shs
BPMC Blueprint Medicines	$128.40 +0.2%	$105.67	$73.04 ▼ $128.43	$8.28B	0.84	1.27 million shs	3.41 million shs
PTCT PTC Therapeutics	$49.60 -1.2%	$48.04	$28.72 ▼ $58.38	$3.98B	0.51	865,062 shs	1.15 million shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	0.00%	-2.67%	+1.26%	-1.16%	-39.92%
BHC Bausch Health Cos	0.00%	+2.58%	+38.50%	-15.07%	-9.26%
BPMC Blueprint Medicines	0.00%	+0.19%	+26.31%	+34.56%	+23.00%
PTCT PTC Therapeutics	0.00%	-2.07%	+9.30%	-11.98%	+37.46%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARWR Arrowhead Pharmaceuticals	3.5871 of 5 stars	3.4	1.0	3.4	2.7	2.5	0.0
BHC Bausch Health Cos	3.6843 of 5 stars	1.9	2.0	4.0	3.9	3.3	0.6
BPMC Blueprint Medicines	1.0236 of 5 stars	2.1	2.0	0.0	1.9	0.8	0.6
PTCT PTC Therapeutics	4.6287 of 5 stars	4.3	4.0	4.4	1.8	0.8	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARWR Arrowhead Pharmaceuticals	2.75	Moderate Buy	$43.71	181.85% Upside
BHC Bausch Health Cos	1.86	Reduce	$7.42	21.39% Upside
BPMC Blueprint Medicines	2.27	Hold	$128.06	-0.27% Downside
PTCT PTC Therapeutics	2.67	Moderate Buy	$65.00	31.05% Upside

Current Analyst Ratings Breakdown

Latest BHC, BPMC, ARWR, and PTCT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	BPMC Blueprint Medicines	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$143.00 ➝ $129.00
6/17/2025	PTCT PTC Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$80.00
6/5/2025	BPMC Blueprint Medicines	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$102.00 ➝ $129.00
6/5/2025	BPMC Blueprint Medicines	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$88.00 ➝ $129.00
6/4/2025	BPMC Blueprint Medicines	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold	$83.00 ➝ $129.00
6/3/2025	BPMC Blueprint Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$132.00
6/3/2025	BPMC Blueprint Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/3/2025	BPMC Blueprint Medicines	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/3/2025	BPMC Blueprint Medicines	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/3/2025	BPMC Blueprint Medicines	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Perform
6/3/2025	BPMC Blueprint Medicines	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARWR Arrowhead Pharmaceuticals	$3.55M	603.36	N/A	N/A	$1.54 per share	10.07
BHC Bausch Health Cos	$9.63B	0.23	$7.64 per share	0.80	($0.89) per share	-6.87
BPMC Blueprint Medicines	$508.82M	16.30	N/A	N/A	$4.70 per share	27.32
PTCT PTC Therapeutics	$806.78M	4.87	N/A	N/A	($14.24) per share	-3.48

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARWR Arrowhead Pharmaceuticals	-$599.49M	-$1.40	N/A	N/A	18.02	N/A	-45.33%	-12.49%	8/6/2025 (Estimated)
BHC Bausch Health Cos	-$46M	-$0.11	N/A	1.31	N/A	-0.41%	-540.45%	5.26%	7/30/2025 (Estimated)
BPMC Blueprint Medicines	-$67.09M	-$2.47	N/A	197.54	N/A	-27.70%	-64.60%	-17.22%	7/30/2025 (Estimated)
PTCT PTC Therapeutics	-$363.30M	$6.51	7.62	N/A	N/A	33.56%	-78.56%	32.11%	8/6/2025 (Estimated)

Latest BHC, BPMC, ARWR, and PTCT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q2 2025	ARWR Arrowhead Pharmaceuticals	-$0.06	$2.75	+$2.81	$2.75	$116.27 million	$542.71 million
5/6/2025	Q1 2025	PTCT PTC Therapeutics	$0.85	$10.04	+$9.19	N/A	$437.16 million	$1.18 billion
5/1/2025	Q1 2025	BPMC Blueprint Medicines	-$0.42	-$0.74	-$0.32	$0.01	$158.31 million	$149.41 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BHC Bausch Health Cos	N/A	N/A	N/A	N/A	N/A
BPMC Blueprint Medicines	N/A	N/A	N/A	N/A	N/A
PTCT PTC Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARWR Arrowhead Pharmaceuticals	0.31	5.15	5.15
BHC Bausch Health Cos	N/A	1.35	0.97
BPMC Blueprint Medicines	1.01	2.80	2.75
PTCT PTC Therapeutics	N/A	3.89	3.85

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARWR Arrowhead Pharmaceuticals	62.61%
BHC Bausch Health Cos	78.65%
BPMC Blueprint Medicines	N/A
PTCT PTC Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
ARWR Arrowhead Pharmaceuticals	4.30%
BHC Bausch Health Cos	8.12%
BPMC Blueprint Medicines	4.21%
PTCT PTC Therapeutics	5.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARWR Arrowhead Pharmaceuticals	400	138.10 million	132.16 million	Optionable
BHC Bausch Health Cos	20,700	370.08 million	340.03 million	Optionable
BPMC Blueprint Medicines	640	64.58 million	61.86 million	Optionable
PTCT PTC Therapeutics	1,410	79.26 million	74.90 million	Optionable

BHC, BPMC, ARWR, and PTCT Headlines

Recent News About These Companies

Sephience™ (sepiapterin) Granted Marketing Authorization by the European Commission for the Treatment of Children and Adults Living with Phenylketonuria (PKU)

June 23 at 7:00 AM | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT

June 22 at 10:00 AM | prnewswire.com

PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Consensus Rating of "Moderate Buy" from Analysts

June 22 at 4:21 AM | marketbeat.com

Truist Initiates PTC Therapeutics (PTCT) Coverage with Buy Rating on Drug Launches

June 20 at 10:27 AM | msn.com

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 19, 2025 | prnewswire.com

PTC Therapeutics (NASDAQ:PTCT) Now Covered by Analysts at Truist Financial

June 19, 2025 | americanbankingnews.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT

June 18, 2025 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT

June 17, 2025 | prnewswire.com

Truist Financial Begins Coverage on PTC Therapeutics (NASDAQ:PTCT)

June 17, 2025 | marketbeat.com

PTCT Investors Have Opportunity to Join PTC Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

June 16, 2025 | businesswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT

June 16, 2025 | accessnewswire.com

PTC Therapeutics, Inc. (NASDAQ:PTCT) Stake Lowered by Assenagon Asset Management S.A.

June 14, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT

June 13, 2025 | accessnewswire.com

Pallas Capital Advisors LLC Makes New $353,000 Investment in PTC Therapeutics, Inc. (NASDAQ:PTCT)

June 13, 2025 | marketbeat.com

PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Acquired by GAMMA Investing LLC

June 13, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT

June 12, 2025 | prnewswire.com

Harbor Capital Advisors Inc. Cuts Stock Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT)

June 12, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT

June 11, 2025 | accessnewswire.com

Brokers Offer Predictions for PTCT FY2026 Earnings

June 10, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT

June 9, 2025 | accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT

June 7, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BHC, BPMC, ARWR, and PTCT Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

$15.51 +0.19 (+1.24%)

Closing price 04:00 PM Eastern

Extended Trading

$15.63 +0.12 (+0.80%)

As of 04:58 PM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Bausch Health Cos NYSE:BHC

$6.11 -0.07 (-1.13%)

Closing price 03:59 PM Eastern

Extended Trading

$6.14 +0.03 (+0.51%)

As of 07:55 PM Eastern

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Blueprint Medicines NASDAQ:BPMC

$128.40 +0.20 (+0.16%)

Closing price 04:00 PM Eastern

Extended Trading

$128.42 +0.01 (+0.01%)

As of 07:36 PM Eastern

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

PTC Therapeutics NASDAQ:PTCT

$49.60 -0.60 (-1.20%)

Closing price 04:00 PM Eastern

Extended Trading

$49.60 -0.01 (-0.01%)

As of 04:53 PM Eastern

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time